NeuroPace Inc RNS System gains favor for targeted seizure interruption

NeuroPace Inc RNS System gains favor for targeted seizure interruption
NeuroPace RNS System preferred

NeuroPace Inc has highlighted a patient's preference for the RNS System over the VNS device for seizure management. The patient reported that the RNS System's ability to stop seizures at their source made it a more attractive option compared to the VNS, which requires detection of symptoms before activation.

This distinction in intervention timing may influence patient choices and clinical decision-making for those seeking effective seizure control. NeuroPace Inc continues to develop neurostimulation therapies aiming to improve quality of life for individuals with epilepsy.

NeuroPace Inc recently hosted a symposium on responsive thalamic neuromodulation for drug-resistant epilepsy at ASSFN2026, drawing strong interest from the clinical community, according to a previous report. The company also presented early Nautilus study results and discussed LGS device feasibility during the ASSFN breakfast session with leading doctors, as noted in an earlier article. These events reflect continued engagement with neuromodulation research in epilepsy treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.